指南与共识

高血压患者原发性醛固酮增多症筛查诊治流程

展开
  • 《高血压患者原发性醛固酮增多症筛查诊治流程》委员会

收稿日期: 2020-07-20

  网络出版日期: 2022-07-14

本文引用格式

中国高血压联盟 . 高血压患者原发性醛固酮增多症筛查诊治流程[J]. 诊断学理论与实践, 2020 , 19(05) : 454 -459 . DOI: 10.16150/j.1671-2870.2020.05.003

参考文献

[1] Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen?[J]. Eur Heart J, 2014, 35(19):1245-1254.
[2] Käyser SC, Dekkers T, Groenewoud HJ, et al. Study hete-rogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis[J]. J Clin Endocrinol Metab, 2016, 101(7):2826-2835.
[3] Monticone S, Burrello J, Tizzani D, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice[J]. J Am Coll Cardiol, 2017, 69(14):1811-1820.
[4] Umpierrez GE, Cantey P, Smiley D, et al. Primary aldo-steronism in diabetic subjects with resistant hypertension[J]. Diabetes Care, 2007, 30(7):1699-1703.
[5] Prejbisz A, Florczak E, Klisiewicz A, et al. Relationship between primary aldosteronism and obstructive sleep apnoea, metabolic abnormalities and cardiac structure in patients with resistant hypertension[J]. Endokrynol Pol, 2013, 64(5):363-367.
[6] Calhoun DA, Nishizaka MK, Zaman MA, et al. Aldo-sterone excretion among subjects with resistant hypertension and symptoms of sleep apnea[J]. Chest, 2004, 125(1):112-117.
[7] Li M, Ge Q, Sheng CS, et al. Clinical characteristics of snoring patients with primary aldosteronism and obstructive sleep apnea-hypopnea syndrome[J]. J Hum Hypertens, 2019, 33(9):693-700.
[8] Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2018, 6(1):41-50.
[9] Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism[J]. J Am Coll Cardiol, 2005, 45(8):1243-1248.
[10] Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5(9):689-699.
[11] Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16):1913-1922.
[12] 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9):727-736.
[13] 冷敏, 刘爱云, 司家峰, 等. 化学发光法检测鲁西健康人群肾素-血管紧张素-醛固酮系统参考范围及影响因素[J]. 国际检验医学杂志, 2018, 39(15):1910-1914.
[14] 常富江, 张雪培, 王声政, 等. 醛固酮腺瘤患者血浆醛固酮、肾素水平分析[J]. 检验医学, 2019, 34(8):722-725.
[15] Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldo-steronism: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38(10):1919-1928.
[16] Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrino-logy Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2016, 175(2):G1-G34.
[17] Wang D, Xu JZ, Chen X, et al. Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography[J]. J Hypertens, 2019, 37(10):2032-2040.
[18] Chen YL, Xu TY, Xu JZ, et al. A speckle tracking echocardiographic study on right ventricular function in primary aldosteronism[J]. J Hypertens, 2020, 38(11):2261-2269.
[19] Rossi GP, Maiolino G, Flego A, et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term[J]. Hypertension, 2018, 71(4):585-591.
[20] Farrugia FA, Zavras N, Martikos G, et al. A short review of primary aldosteronism in a question and answer fa-shion[J]. Endocr Regul, 2018, 52(1):27-40.
[21] 陈绍行, 杜月凌, 张瑾, 等. 在高血压患者中筛选原发性醛固酮增多症国人血浆醛固酮/肾素活性比值标准的探讨[J]. 中华心血管病杂志, 2006, 34(10):868-872.
[22] 张炜, 汤正义, 吴景程, 等. 静脉盐水负荷试验在原发性醛固酮增多症诊断中的应用[J]. 上海交通大学学报(医学版), 2007, 27(6):703-705.
[23] Zhang Y, Niu W, Zheng F, et al. Identifying unilateral disease in Chinese patients with primary aldosteronism by using a modified prediction score[J]. J Hypertens, 2017, 35(12):2486-2492.
[24] Scholl UI, Stölting G, Schewe J, et al. CLCN2 chloride channel mutations in familial hyperaldosteronism type Ⅱ[J]. Nat Genet, 2018, 50(3):349-354.
[25] Zheng FF, Zhu LM, Nie AF, et al. Clinical characteristics of somatic mutations in Chinese patients with aldo-sterone-producing adenoma[J]. Hypertension, 2015, 65(3):622-628.
[26] Velema M, Dekkers T, Hermus A, et al. Quality of life in primary aldosteronism: a comparative effectiveness study of adrenalectomy and medical treatment[J]. J Clin Endocrinol Metab, 2018, 103(1):16-24.
[27] Hundemer GL, Curhan GC, Yozamp N, et al. Renal outcomes in medically and surgically treated primary aldo-steronism[J]. Hypertension, 2018, 72(3):658-666.
[28] Steichen O, Lorthioir A, Zinzindohoue F, et al. Outcomes of drug-based and surgical treatments for primary aldo-steronism[J]. Adv Chronic Kidney Dis, 2015, 22(3):196-203.
文章导航

/